Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN02385, INCAGN02390, and INCMGA00012 in Advanced Malignancies and Melanoma
NCT04370704Phase 2Completed
- Sponsor
- Incyte
- Start
- Jul 2020
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tuparstobart, verzistobart in melanoma, solid tumor, sponsored by Incyte. Started Jul 2020; status: completed.
02
Drugs
tuparstobartverzistobart
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT04370704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370704.